Relationship of sRANKL level and vascular calcification score to cardiovascular events in maintenance hemodialysis patients

Blood Purification

Volumn 28, Issue 4, 2009, Pages 342-345

  Wei, Tao ^a   Wang, Mei ^a   Wang, Mi ^a   Gan, Liang Ying ^a   Li, Xin ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Cardiovascular events; Hemodialysis; Soluble receptor activator of nuclear factor B ligand; Vascular calcification

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

ADULT; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; MALE; MORTALITY; PELVIS RADIOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; CALCINOSIS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHORUS; RANK LIGAND; REGRESSION ANALYSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 69549107459     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000232941     Document Type: Article

References (13)

1. Tono S, Shioi A, Lkari Y, et al: Vascular calcification in chronic kidney disease. J Bone Miner Metab 2006; 24: 176-181.
2. Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567.
3. Khosla S: Minireview: The OPG/RANKL/ RANK system. Endocrinology 2001; 142: 5050-5055.
4. Kiechl S, Scheet G, Schwaiger J, et al: Soluble receptor activator of nuclear factor-κB ligand and risk for cardiovascular disease. Circulation 2007; 116: 385-391.
5. Adragao T, Pires A, Lucas C, et al: A simple vascular calcification score predicts cardiovascular risk in hemodialysis patients. Nephrol Dial Transplant 2004; 19: 1480-1488.
6. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112-S119.
7. Holly K, Robert T, Ronald P, Richard Cooper, Ronald V: Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J Am Soc Nephrol 2005; 16: 507-513.
8. Stefan K, Georg S, Judith E: Soluble receptor activator of nuclear factor- κ B ligand and risk for cardiovascular disease. Circulation 2007; 116: 385-391.
9. Gori F, Hofbauer LC, Dunstan CR, et al: The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000; 141: 4768-4776.
10. Schoppet M, Schaefer JR, Hofbauer LC: Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. Circulation 2003; 107:e76.
11. Bezerra MC, Calomein GD, Caparbo VF, et al: Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arthritis. Rheumatology (Oxford) 2005; 44: 1503-1506.
12. Nitta K, Akiba T, Uchida K, et al: Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1886-1889.
13. Moe SM, Reslerova M, Ketteler M, et al: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67: 2295-2304.